This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by BRAUNSTEIN, G. D. Articles by WINIKOFF, J. Search for Related Content PubMed PubMed Citation Articles by BRAUNSTEIN, G. D. Articles by WINIKOFF, J.

Characterization of Antihuman Chorionic Gonadotropin Serum Antibody Appearing after Ovulation Induction^*

Department of Medicine, Cedars-Sinai Medical Center-UCLA School of Medicine Los Angeles, California 90048
The Department of Obstetrics and Gynecology, Kaiser Permanente Los Angeles, California 90048

Address requests for reprints to: Glenn D. Braunstein, M.D., Room 516, Schuman Building, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, California 90048.

After repeated im courses of menopausal gonadotropins and hCG, a factor was found in a woman’s serum which preferentially bound the intact hCG molecule (nanograms or milliinternational units required for 50% displacement of [¹²⁵I] hCG: hCG, 9.2 ng; APL, 74 mIU; Pergonal, 400 mlU; LER 960, 900 ng; and FSH and TSH -subunits, hCG β-subunit, and LH (β-subunit, >1000 ng). This factor had a low affinity (K_a = 5.8 x 10⁹ liters/M) and high capacity (binding capacity, 5.5 x 10^–11 M/liter) for hCG, was isolated with the immunoglobulin G fraction of the patient’s serum, and coeluted with immunoglobulin G from a Sepharose CL-6B-200 column. Preincubation of hCG with this fraction did not reduce the in vitro biological activity of the hCG in the hypophysectomized rat ventral prostate weight assay. Similarly, there was no gonadal resistance to hCG in the patient, since ovulation could still be induced with hCG, and both progesterone and 17-hydroxyprogesterone levels as well as duration of the luteal phase increased after repeated hCG injections. This serum factor prolonged the half-life of injected hCG in the patient’s circulation (t = 9.4 days in patient vs. 1.3 days in controls). The titer of the factor transiently decreased with the exogenous administration of hCG. No binding of the serum factor to human placental tissue could be demonstrated by immunohistochemical techniques.

Thus, this factor behaves similarly to the antibodies frequently found after the injection of other polypeptide hormones, in that it serves as a high capacity reservoir of the hormone but does not significantly reduce its biological activity. These results also indicate that the factor requires the intact tertiary structure of the hCG molecule for immune recognition.

^* This work was supported in part by NIH Training Grant 5T32-AM-07426 and a BioScience Laboratories Research Fellowship (J. W.).

Received March 28, 1983.